UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

HDFCCC Overview Working Together Advancing the Understanding and Treatment of Cancer Multi-Disciplinary Research Programs • Breast Oncology • Cancer Control • Cancer Genetics • Cancer, Immunity, and Microenvironment • Developmental Therapeutics • Hematopoietic Malignancies • Neurologic Oncology • Pediatric Malignancies • Prostate Cancer • Tobacco Control Multi-Disciplinary Clinical Programs • GU Oncology (non Prostate) • GI (includes Pancreas Cancer) • Thoracic Oncology • Cutaneous Oncology • Head and Neck Cancer • Sarcoma • Endocrine • Gynecologic Oncology • Breast Oncology • Prostate Cancer Key Initiatives • Cancer Imaging • Cancer Immunotherapeutics • Global Oncology • Center for BRCA Research • UCSF 500 • Target Validation Initiative Advancing the Next Wave of Cancer Treatment Breakthroughs Whether it is pioneering novel clinical trial designs, discovering, developing and bringing to the clinic revolutionary treatments such as immunotherapies or harnessing the power of big data to drive faster, personalized and more effective cures, UCSF leads in advancing the next wave of cancer treatment breakthroughs. With a culture of collaboration, a commitment to excellence and access to cutting-edge laboratory and clinical technologies, UCSF faculty work tirelessly to improve clinical outcomes for cancer patients everywhere.
HDFCCC Overview Core Capabilities Supporting Our Programs • Biostatistics • Clinical Research Support • Genome Analysis • Laboratory for Cell Analysis • Immunohistochemistry & Molecular Pathology • Mouse Pathology • Preclinical Therapeutic Testing • Bio-specimen Banking • Tobacco Biomarkers • Bioinformatics • Computational Biology Approximately one-quarter of the University’s ~2,200 full-time faculty members work in cancer research or cancer care. UCSF consistently ranks among the top U.S. biomedical research organizations in cancer-specific federal funding. In 2015, UCSF received more than $85M from the National Cancer Institute. 5
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3: HDFCCC Overview A Designated NCI Co
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Phase II trials of ce
Page 11 and 12: Presentations CRS-207 immunotherapy
Page 13 and 14: Presentations Long-term OS for pati
Page 15 and 16: Presentations Randomized phase 2 st
Page 17 and 18: Presentations Genomic Profiling to
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25 and 26: Presentations IMAAGEN trial safety
Page 27 and 28: Presentations Immunogenicity of sip
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33 and 34: Presentations Correlation between m
Page 35 and 36: Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56:
Presentations Phase II trial with t
Page 57 and 58:
Presentations Academic and Communit
Page 59 and 60:
Presentations Prevention of everoli
Page 61 and 62:
Presentations A phase 2 randomized,
Page 63 and 64:
Presentations PD-L1 expression, Can
Page 65 and 66:
Presentations The Heart of the Matt
Page 67 and 68:
Presentations 4-year results of the
Page 69 and 70:
Presentations Impact of landmark re
Page 71 and 72:
Presentations Phase II study of ali
Page 73 and 74:
Presentations Can lay health worker
Page 75 and 76:
Presentations Medical Management of
Page 77 and 78:
Presentations Prospective evaluatio
Page 79 and 80:
Presentations A phase II randomized
Page 81 and 82:
Presentations Early, molecular dete
Page 83 and 84:
Presentations Metastatic melanoma,
Page 85 and 86:
Presentations Three-year overall su
Page 87 and 88:
Presentations Heritage: A phase III
Page 89 and 90:
Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?